Atlas Trials

NK T-Cell Lymphoma

25 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch NK T-Cell Lymphoma

RecordFirmDate
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma (NCT05208853)Zhejiang University2022-02-10
Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma (NCT04899414)Peking University2021-05-18
A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma (NCT04425070)Antengene Corporation2020-08-18
Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma (NCT04230330)National Cancer Centre, Singapore2019-12-12
CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia (NCT04004637)PersonGen BioTherapeutics (Suzhou) Co., Ltd.2019-08-25
Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies (NCT04008394)Union Hospital, Tongji Medical College, Huazhong University of Science and Technology2019-07-03
PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma (NCT04038411)Mingzhi Zhang2019-04-01
PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma (NCT03701022)Peking University2018-10-20
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types (NCT03012620)UNICANCER2017-07-05
A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma (NCT04490590)Mingzhi Zhang2016-10-01
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) (NCT02588651)Deepa Jagadeesh2016-06-17
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas (NCT01445535)National Cancer Institute (NCI)2009-01-13

Track NK T-Cell Lymphoma automatically

Every clearance here is in the API, with alerts when new ones post.